Abstract
Over‐expression of the HER2 oncogene is seen in 20% of all breast cancers. In this population of women, 30% will present with CNS metastasis following the initial diagnosis, and 50% of these women will die of progressive CNS disease. Treatment options are limited and patients’ quality of life is usually compromised.Our laboratory has developed a model of CNS metastasis of a human HER2 positive breast cancer cell line which can be used to evaluate new therapies. We have found that a left ventricular, percutaneous injection of 1×106 cells into athymic rats causes detectable CNS metastases by 4 weeks in 80–90% of subjects. We are using this model to develop novel strategies for blocking CNS metastasis and treating CNS metastasis once it occurs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
